Study wrapper · #1241
Protective and restorative effects of hexarelin on MPTP-induced lung injury in mice.
Editor's note
A small single-model animal study with immunohistochemistry as its main readout, so the findings sit early on the evidence ladder and say nothing about human lung injury. The interesting wrinkle is the dose-timing result: post-exposure administration outperformed pre-exposure, the opposite of what a simple antioxidant story would predict. Hexarelin's non-growth-hormone tissue-protective effects have been reported before in cardiac and gastric models, and this adds pulmonary tissue to that list. Independent replication with functional endpoints would be the next step.
Plain-language abstract
In this mouse experiment, 50 animals received an intranasal dose of MPTP, a neurotoxin used to model Parkinson-like injury, which also damaged their lungs - thickened alveolar walls, edema, congestion, and inflammatory infiltration. Hexarelin, a growth hormone secretagogue, was given by injection either before or after the toxin exposure. Both timings reduced visible tissue damage and improved markers of oxidative stress, inflammation, and cell death, with lower Caspase-3 and IL-6 staining and higher superoxide dismutase. Giving hexarelin after the toxin worked better than giving it beforehand, which the authors attribute to cytoprotective pathways being actively engaged during ongoing injury.